Grifols renewed its 2009 collaboration agreement with the EASL-Chronic Liver Failure Consortium (EASL-CLIF Consortium)

By EASL, Grifols July 15,2013

On July 10, 2013, Grifols has renewed its collaboration agreement with the EASL-CLIF Consortium for a further four years. Under this agreement, Grifols will increase its financial contribution with three millions euros, in the form of unrestricted grant. The consortium has recently published in Gastroenterology (June 2013) its first core study, the CANONIC investigation, aimed to assess the diagnostic criteria, prevalence, clinical features, prognosis and mechanism of Acute on Chronic Liver Failure in cirrhosis. The study consisted in a prospective, multicenter, European, observational study in 1343 patients admitted to hospital with acute decompensation of Cirrhosis. Twenty-nine hospitals from 9 countries participated in the study, 27000 biological samples were obtained, and more than 30 ancillary studies will derive from this core CANONIC study.

The EASL-CLIF Consortium, therefore, has proved to be an effective tool to perform complex studies in large series of patients within a short period of time. In its second 4 years period the Consortium is planning to perform several large randomized controlled therapeutic trials in patients with cirrhosis. Grifols is committed to support research in cirrhosis since many years ago. In fact, a research consortium with similar aims to the EASL-CLIF Consortium, the North American Consortium for the End-Stage Liver Disease, has been created in USA and Canada with the support of Grifols.

Read the full press release here.